Peptidron Secures U.S. Patent for Long-Acting Semaglutide Formulation

Peptidron, an innovative new drug development company specializing in peptide-based therapies, has secured a U.S. patent for its long-acting formulation technology that includes semaglutide.

According to Peptidron on June 19, the company has completed the payment procedures for a patent that received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). This payment is a follow-up step after the USPTO’s decision to grant the patent, and the official registration will be finalized following the USPTO’s issuance procedures.

This patent covers long-acting microsphere formulations containing semaglutide or its pharmaceutically acceptable salts. In particular, it includes formulation design technology that utilizes a combination of specific drug content and biodegradable polymers to achieve sustained-release properties, and the technical scope applies to the treatment of obesity, diabetes, and metabolic disorders.

Peptidron recently presented research results on PT403, a once-monthly, long-acting candidate for obesity and diabetes treatment containing semaglutide, at the American Diabetes Association (ADA 2026) conference in New Orleans, USA. The company emphasized that with the payment for the U.S. patent registration, the process of securing U.S. patent rights for the core formulation technology of PT403 is now in its final stage.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that is leading the global obesity and diabetes treatment market. As the market for obesity and metabolic disorder treatments grows, interest is rising in long-acting formulation technologies that can improve dosing convenience. Peptidron is developing next-generation long-acting therapeutics based on its proprietary SmartDepot™ platform, which offers stable drug release characteristics and enhanced dosing convenience.

A Peptidron spokesperson stated, "This registration fee payment is an important follow-up procedure for the U.S. patent registration of our long-acting semaglutide formulation technology. Following the presentation of PT403 research results at ADA 2026, the process to secure U.S. intellectual property rights for our core formulation technology is also entering its final stage. We will continue to strengthen the global competitiveness of our SmartDepot™ platform in the obesity and metabolic disorder field."

Meanwhile, Peptidron is developing PT403, a once-monthly long-acting candidate for obesity and diabetes treatment based on the SmartDepot™ platform, and is pursuing strategies to expand its global commercialization and intellectual property portfolio in parallel with R&D progress.

This content was produced with the assistance of AI translation services.